How does ketoconazole affect MMAE exposure when co-administered with brentuximab vedotin?

Ketoconazole, a strong CYP3A4 and P-gp inhibitor, increased MMAE exposure by approximately 73% without altering brentuximab vedotin plasma exposure, potentially increasing neutropenia incidence; if neutropenia develops, the prescribing information’s dosing recommendations should be followed.